Phase 2 Study Finds Nivolumab-Ipilimumab Combo Shows Activity in Metastatic Uveal Melanoma

Source: cancernetwork, November 2020

A single-arm phase 2 study published in the Journal of Clinical Oncology found that the combination regimen of nivolumab (Opdivo) plus ipilimumab (Yervoy) demonstrates activity in metastatic uveal melanoma, with deep and sustained confirmed responses.

Results from this study, as well as the Spanish GEM-1402 study, suggest that this combination is active and should be considered for this patient population. However, additional research is still necessary to characterize the molecular and genomic signatures of responders and nonresponders.

“These data were intended to serve as a new benchmark in uveal melanoma, and the results of the current study demonstrate improvement,” the authors wrote.

READ THE ORIGINAL FULL ARTICLE